Kalydeco (Ivacaftor)

Ivacaftor binds to the CFTR protein on the cell surface and increases the likelihood that the chloride channel stays open. This action enhances chloride ion transport across epithelial cells, leading to better hydration of airway surfaces and thinner mucus in patients with responsive mutations.

The dosage of Kalydeco is individualized and determined by the prescribing clinician based on the patient’s age, weight, and specific CFTR mutation. Patients should follow the prescriber’s instructions and not adjust the dose without medical guidance.

Safety data for ivacaftor in pregnancy and lactation are limited. The potential risks and benefits should be discussed with a healthcare professional. Women who are pregnant, planning to become pregnant, or breastfeeding should consult their physician before using Kalydeco.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Kalydeco is a CFTR potentiator that directly enhances the function of the defective chloride channel, whereas other therapies such as lumacaftor/ivacaftor combine a corrector and potentiator to improve protein processing and function. The choice depends on the patient’s specific CFTR mutation profile and clinical response.

Kalydeco tablets should be stored at ambient temperature, preferably below 25 °C. Keep the medication in its original packaging, protect it from moisture, and store it out of direct sunlight to maintain stability.

Kalydeco is taken orally as a tablet. For optimal absorption, it should be swallowed with a fat‑containing meal. Patients must follow the dosing schedule prescribed by their healthcare provider.

Serious risks include liver enzyme elevations, which require regular monitoring, and rare but severe skin reactions such as Stevens‑Johnson syndrome. Pulmonary hemorrhage has also been reported. Patients should report any unusual symptoms promptly to their clinician.

Kalydeco is not indicated for patients without the specific CFTR gating mutations it targets. Individuals with severe liver disease, known hypersensitivity to ivacaftor, or those taking contraindicated strong CYP3A4 inhibitors should avoid using this medication.